<DOC>
	<DOCNO>NCT01222611</DOCNO>
	<brief_summary>This study examine impact fosamprenavir part ART virological , immunological clinical parameter genotype 1 HCV infection HIV co-infected subject . Fosamprenavir could direct immune-mediated activity HCV . If show true , change HCV viral load biological characteristic could demonstrate .</brief_summary>
	<brief_title>HCV Evolution HIV/HCV ( Genotype 1 ) Coinfected Patients Treated With Fosamprenavir</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>Age &gt; 18 yo HIV/HCV coinfected patient HCV detectable viremia 2 determination separate least 6 month . HCV genotype 1 Currently receive ART include 2NRTI+1 PI/r ( exclude FPV ) 1 NNRTI , without change last 6 month HIV RNA &lt; 50 copies/mL last 6 month Previous anti HCV treatment Foreseeable HCV treatment next 12 month Acute HCV infection Active opportunistic infection HIV FPV resistance mutation Current previous treatment FPV Chronic hepatitis B Current alcohol consumption great 20 g per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>HCV</keyword>
	<keyword>HIV/HCV</keyword>
	<keyword>Coinfection</keyword>
	<keyword>Fosamprenavir</keyword>
</DOC>